93 related articles for article (PubMed ID: 17374986)
1. Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy.
Hoffmann D; Grunwald T; Kuate S; Wildner O
Cancer Biol Ther; 2007 Apr; 6(4):510-8. PubMed ID: 17374986
[TBL] [Abstract][Full Text] [Related]
2. Synergy between expression of fusogenic membrane proteins, chemotherapy and facultative virotherapy in colorectal cancer.
Hoffmann D; Bangen JM; Bayer W; Wildner O
Gene Ther; 2006 Nov; 13(21):1534-44. PubMed ID: 16791286
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Faruk M; Ibrahim S; Aminu SM; Adamu A; Abdullahi A; Suleiman AM; Rafindadi AH; Mohammed A; Iliyasu Y; Idoko J; Saidu R; Randawa AJ; Musa HS; Ntekim A; Shah KZ; Abubakar S; Adoke KU; Manko M; Awasum CA
PLoS One; 2021; 16(1):e0245581. PubMed ID: 33465114
[TBL] [Abstract][Full Text] [Related]
4. Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
Hoffmann D; Bayer W; Wildner O
Hum Gene Ther; 2007 May; 18(5):435-50. PubMed ID: 17518612
[TBL] [Abstract][Full Text] [Related]
5. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus.
Ayala-Breton C; Russell LO; Russell SJ; Peng KW
J Virol; 2014 Aug; 88(15):8332-9. PubMed ID: 24829351
[TBL] [Abstract][Full Text] [Related]
6. Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice.
Johnson JE; McNeil LK; Megati S; Witko SE; Roopchand VS; Obregon JH; Illenberger DM; Kotash CS; Nowak RM; Braunstein E; Yurgelonis I; Jansen KU; Kalyan NK; Sidhu MK
Immunol Lett; 2013 Feb; 150(1-2):134-44. PubMed ID: 23261719
[TBL] [Abstract][Full Text] [Related]
7. Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.
Chang G; Xu S; Watanabe M; Jayakar HR; Whitt MA; Gingrich JR
J Urol; 2010 Apr; 183(4):1611-8. PubMed ID: 20172545
[TBL] [Abstract][Full Text] [Related]
8. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
9. In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.
Hoffmann D; Bayer W; Wildner O
World J Gastroenterol; 2007 Jun; 13(22):3063-70. PubMed ID: 17589921
[TBL] [Abstract][Full Text] [Related]
10. Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy.
Hoffmann D; Wildner O
Mol Cancer Ther; 2006 Aug; 5(8):2013-22. PubMed ID: 16928822
[TBL] [Abstract][Full Text] [Related]
11. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins.
Ayala-Breton C; Barber GN; Russell SJ; Peng KW
Hum Gene Ther; 2012 May; 23(5):484-91. PubMed ID: 22171635
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia.
Hoffmann D; Grunwald T; Bayer W; Wildner O
World J Gastroenterol; 2008 Mar; 14(12):1842-50. PubMed ID: 18350621
[TBL] [Abstract][Full Text] [Related]
13. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer.
Hoffmann D; Bayer W; Grunwald T; Wildner O
Mol Cancer Ther; 2007 Jul; 6(7):1942-50. PubMed ID: 17620425
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of twenty-one human adenovirus types and one infectivity-enhanced adenovirus for the treatment of malignant melanoma.
Hoffmann D; Bayer W; Heim A; Potthoff A; Nettelbeck DM; Wildner O
J Invest Dermatol; 2008 Apr; 128(4):988-98. PubMed ID: 17960177
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors.
Hoffmann D; Bayer W; Wildner O
Int J Mol Med; 2007 Nov; 20(5):673-81. PubMed ID: 17912460
[TBL] [Abstract][Full Text] [Related]
17. Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps.
Ternette N; Stefanou D; Kuate S; Uberla K; Grunwald T
Virol J; 2007 Jun; 4():51. PubMed ID: 17550613
[TBL] [Abstract][Full Text] [Related]
18. Combination of FOLFOXIRI Drugs with Oncolytic Coxsackie B3 Virus PD-H Synergistically Induces Oncolysis in the Refractory Colorectal Cancer Cell Line Colo320.
Girod M; Geisler A; Hinze L; Elsner L; Dieringer B; Beling A; Kurreck J; Fechner H
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891807
[TBL] [Abstract][Full Text] [Related]
19. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion.
Kahn JS; Schnell MJ; Buonocore L; Rose JK
Virology; 1999 Feb; 254(1):81-91. PubMed ID: 9927576
[TBL] [Abstract][Full Text] [Related]
20. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
